X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (116) 116
oncology (110) 110
female (94) 94
index medicus (91) 91
chemotherapy (80) 80
breast neoplasms - drug therapy (76) 76
dose-dense (74) 74
breast cancer (65) 65
cancer (61) 61
middle aged (57) 57
antineoplastic combined chemotherapy protocols - therapeutic use (50) 50
adult (47) 47
cyclophosphamide (47) 47
aged (44) 44
chemotherapy, adjuvant (38) 38
randomized-trial (38) 38
adjuvant treatment (37) 37
treatment outcome (37) 37
dose-dense chemotherapy (36) 36
adjuvant chemotherapy (34) 34
paclitaxel (34) 34
doxorubicin (33) 33
therapy (32) 32
antineoplastic combined chemotherapy protocols - adverse effects (30) 30
breast neoplasms - pathology (30) 30
disease-free survival (30) 30
epirubicin (30) 30
antineoplastic combined chemotherapy protocols - administration & dosage (29) 29
drug administration schedule (29) 29
dose-response relationship, drug (28) 28
medicine & public health (28) 28
anthracyclines (25) 25
docetaxel (25) 25
paclitaxel - administration & dosage (25) 25
women (24) 24
care and treatment (23) 23
prognosis (23) 23
combination chemotherapy (22) 22
neoadjuvant chemotherapy (22) 22
phase-iii trial (21) 21
cyclophosphamide - administration & dosage (20) 20
fluorouracil (20) 20
hematology, oncology and palliative medicine (20) 20
male (20) 20
research (20) 20
analysis (19) 19
clinical trials (19) 19
follow-up (18) 18
methotrexate (18) 18
neoadjuvant therapy (18) 18
antineoplastic agents - therapeutic use (17) 17
breast neoplasms - mortality (17) 17
cisplatin (17) 17
drug therapy (17) 17
health aspects (17) 17
fluorouracil - administration & dosage (16) 16
trial (16) 16
bladder cancer (15) 15
cancer therapies (15) 15
colony-stimulating factor (15) 15
survival rate (15) 15
antineoplastic agents - adverse effects (14) 14
epirubicin - administration & dosage (14) 14
randomized controlled trials as topic (14) 14
risk factors (14) 14
survival (14) 14
taxanes (14) 14
trastuzumab (14) 14
antineoplastic agents - administration & dosage (13) 13
breast neoplasms - surgery (13) 13
dose-dense methotrexate (13) 13
doxorubicin - administration & dosage (13) 13
filgrastim (13) 13
neoplasm staging (13) 13
carcinoma (12) 12
cisplatin - administration & dosage (12) 12
deoxycytidine - analogs & derivatives (12) 12
doxorubicin plus cyclophosphamide (12) 12
hematology (12) 12
metastasis (12) 12
methotrexate - administration & dosage (12) 12
obstetrics & gynecology (12) 12
survival analysis (12) 12
deoxycytidine - administration & dosage (11) 11
follow-up studies (11) 11
phase-ii (11) 11
phase-iii (11) 11
retrospective studies (11) 11
surgical adjuvant breast (11) 11
taxoids - administration & dosage (11) 11
tumors (11) 11
urinary bladder neoplasms - drug therapy (11) 11
urology & nephrology (11) 11
breast-cancer (10) 10
chemotherapy, adjuvant - methods (10) 10
cyclophosphamide - adverse effects (10) 10
lymphatic metastasis (10) 10
patient outcomes (10) 10
pharmacology & pharmacy (10) 10
review (10) 10
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Urology, ISSN 0302-2838, 2015, Volume 69, Issue 5, pp. 855 - 862
Abstract Background Gene expression profiling (GEP) suggests there are three subtypes of muscle-invasive urothelial cancer (UC): basal, which has the worst... 
Urology | Basal | Urothelial cancer | Dose-dense methotrexate cisplatin | Gene expression profiling | Luminal | Neoadjuvant | Subtype | Bevacizumab | p53 | METASTASIS | SUBTYPES | TUMORS | UROLOGY & NEPHROLOGY | CYSTECTOMY | CARCINOMA | INVASIVE BLADDER-CANCER | Urinary Bladder Neoplasms - classification | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Humans | Middle Aged | Carcinoma, Transitional Cell - secondary | Transcriptome | Bone Neoplasms - secondary | Male | Gene Expression Profiling | Vinblastine - administration & dosage | Tumor Suppressor Protein p53 - genetics | Cisplatin - administration & dosage | Urinary Bladder Neoplasms - genetics | Urinary Bladder Neoplasms - pathology | Adult | Female | Neoadjuvant Therapy | Chemotherapy, Adjuvant | Carcinoma, Transitional Cell - genetics | Doxorubicin - administration & dosage | Bevacizumab - administration & dosage | Proportional Hazards Models | Survival Rate | Treatment Outcome | Urinary Bladder Neoplasms - drug therapy | Carcinoma, Transitional Cell - classification | Cystectomy | Carcinoma, Transitional Cell - drug therapy | Methotrexate - administration & dosage | Aged | Neoplasm Staging | Antimitotic agents | Anthracyclines | Patient outcomes | Adjuvant treatment | Product development | Genetic aspects | Tumor proteins | Antineoplastic agents | Gene expression | Cancer | Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin
Journal Article
British Journal of Haematology, ISSN 0007-1048, 09/2017, Volume 178, Issue 6, pp. 927 - 935
Summary The optimal therapeutic approach for young diffuse large B‐cell lymphoma (DLBCL) patients with high‐intermediate and high‐risk age‐adjusted... 
dose‐dense rituximab | intensive chemotherapy | diffuse large B‐cell lymphoma | aaIPI | high dose methotrexate | dose-dense rituximab | diffuse large B-cell lymphoma | RESPONSE CRITERIA | FOLLOW-UP | YOUNG-PATIENTS | OPEN-LABEL | CHEMOTHERAPY | HIGH-RISK PATIENTS | NON-HODGKIN-LYMPHOMA | OPTIMIZATION | MABTHERA INTERNATIONAL TRIAL | HEMATOLOGY | ELDERLY-PATIENTS | Cyclophosphamide - administration & dosage | Prednisone - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prognosis | Drug Administration Schedule | Follow-Up Studies | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Treatment Outcome | Positron Emission Tomography Computed Tomography | Rituximab - administration & dosage | Lymphoma, Large B-Cell, Diffuse - diagnostic imaging | Lymphoma, Large B-Cell, Diffuse - therapy | Stem Cell Transplantation - methods | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - administration & dosage | Adult | Female | Methotrexate - administration & dosage | Cohort Studies | Doxorubicin - administration & dosage | Medical research | Autografts | Anthracyclines | Corticosteroids | Patient outcomes | Cyclophosphamide | Chemotherapy | Stem cells | Medicine, Experimental | Lymphomas | Dosage and administration | Comparative analysis | Methotrexate | Prednisolone | Cancer | Statistical analysis | Rituximab | Transplantation | Regression analysis | Patients | Survival | Vincristine | Lymphoma | Optimization | Confidence intervals | Regression models | Daunorubicin | Motivation | Lymphocytes B | Medical prognosis | Remission
Journal Article
LANCET ONCOLOGY, ISSN 1470-2045, 07/2017, Volume 18, Issue 7, pp. 929 - 945
Background Adjuvant chemotherapy for early breast cancer has improved outcomes but causes toxicity. The UK TACT2 trial used a 2 x 2 factorial design to test... 
WOMEN | METAANALYSIS | ONCOLOGY | DOSE-DENSE | DOCETAXEL | CHEMOTHERAPY | PACLITAXEL
Journal Article
Journal Article
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, ISSN 1540-1405, 10/2017, Volume 15, Issue 10, pp. 1240 - 1267
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on systemic therapy for muscle-invasive... 
PHASE-III TRIAL | ADJUVANT CHEMOTHERAPY | GEMCITABINE PLUS CISPLATIN | NEOADJUVANT CHEMOTHERAPY | ONCOLOGY | URINARY-BLADDER | TRANSITIONAL-CELL CARCINOMA | LONG-TERM OUTCOMES | RADICAL CYSTECTOMY | DOSE-DENSE METHOTREXATE | METASTATIC UROTHELIAL CARCINOMA
Journal Article
Lancet Oncology, ISSN 1470-2045, 2005, Volume 6, Issue 11, pp. 886 - 898
Journal Article
Annals of Oncology, ISSN 0923-7534, 09/2011, Volume 22, Issue 9, pp. 1988 - 1998
Background: Preoperative chemotherapy is a recommended treatment of both primary operable and locally advanced breast cancer. Strategies to improve efficacy... 
Neoadjuvant chemotherapy | Pathological complete response | Darbepoetin alfa | Primary breast cancer | Dose-dense chemotherapy | Dose-intensified chemotherapy | pathological complete response | primary breast cancer | COLONY-STIMULATING FACTOR | CYCLOPHOSPHAMIDE | PRIMARY SYSTEMIC TREATMENT | ADJUVANT TREATMENT | dose-intensified chemotherapy | EPOETIN-ALPHA | DOCETAXEL | COMPLETE ERADICATION | dose-dense chemotherapy | neoadjuvant chemotherapy | ONCOLOGY | INTERNATIONAL EXPERT PANEL | darbepoetin alfa | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Epirubicin - administration & dosage | Cyclophosphamide - adverse effects | Filgrastim | Dose-Response Relationship, Drug | Young Adult | Erythropoietin - analogs & derivatives | Fluorouracil - administration & dosage | Fluorouracil - adverse effects | Adult | Female | Neoadjuvant Therapy | Chemotherapy, Adjuvant | Paclitaxel - administration & dosage | Erythropoietin - administration & dosage | Polyethylene Glycols | Hemoglobins - metabolism | Paclitaxel - adverse effects | Breast Neoplasms - drug therapy | Preoperative Care | Recombinant Proteins - administration & dosage | Methotrexate - adverse effects | Breast Neoplasms - pathology | Breast Neoplasms - blood | Methotrexate - administration & dosage | Aged | Patient Compliance | Epirubicin - adverse effects | Granulocyte Colony-Stimulating Factor - administration & dosage
Journal Article
Annals of Oncology, ISSN 0923-7534, 04/2013, Volume 24, Issue 4, pp. 1011 - 1017
Journal Article
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, ISSN 1422-0067, 02/2019, Volume 20, Issue 4, p. 793
Journal Article
Journal Article
ANNALS OF ONCOLOGY, ISSN 0923-7534, 09/2011, Volume 22, Issue 9, pp. 1999 - 2006
Journal Article
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, ISSN 1540-1405, 10/2016, Volume 14, Issue 10, pp. 1213 - 1224
These NCCN Guidelines Insights discuss the major recent updates to the NCCN Guidelines for Bladder Cancer based on the review of the evidence in conjunction... 
PHASE-III TRIAL | BACILLUS-CALMETTE-GUERIN | GEMCITABINE PLUS CISPLATIN | GROUP RANDOMIZED PHASE-3 | NEOADJUVANT CHEMOTHERAPY | ONCOLOGY | TRANSITIONAL-CELL CARCINOMA | HIGH-RISK TA | DOSE-DENSE METHOTREXATE | T1 PAPILLARY CARCINOMA | ADVANCED UROTHELIAL CANCER
Journal Article
World Journal of Urology, ISSN 0724-4983, 02/2016, Volume 34, Issue 2, pp. 157 - 162
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 4/2012, Volume 132, Issue 2, pp. 609 - 619
Journal Article